Table 1.
Descriptive Characteristics and Antibody Titers of NH-COVAIR Study Participants
| Characteristic | Previous SARS-CoV-2 Infection (n = 39) | SARS-CoV-2 Naive (n = 47) |
|---|---|---|
| Age, y (SD) | 80.8 (10.1) | 81.4 (11.5) |
| Gender, female (%) | 23 (59.0) | 33 (70.2) |
| Body Mass Index, m/kg2 (SD) | 27.8 (5.8) | 26.1 (6.9) |
| Cognitive Status | ||
| Mild cognitive impairment (%) | 9 (23.1) | 14 (29.8) |
| Dementia (%) | 7 (17.95) | 13 (27.7) |
| Medical history | ||
| Comorbidity count (IQR) | 5 (4–7) | 4 (3–6) |
| Diabetes (%) | 7 (17.8) | 11 (23.4) |
| Neurodegenerative disorder (%) | 6 (15.4) | 4 (8.5) |
| Solid tumor (%) | 5 (15.4) | 5 (10.6) |
| Chronic obstructive pulmonary disease (%) | 7 (18.0) | 8 (17.0) |
| Stroke (%) | 10 (25.6) | 9 (19.2) |
| Congestive cardiac failure (%) | 8 (20.5) | 3 (6.8) |
| Myocardial Infarction (%) | 4 (10.3) | 4 (8.5) |
| Medication history | ||
| Number of regular medications (IQR) | 13 (10–18) | 13 (11–16) |
| Regular inhaled steroid (%) | 5 (12.8) | 4 (8.5) |
| Regular oral steroid (%) | 2 (5.1) | 2 (4.3) |
| Regular NSAID (%) | 11 (28.2) | 16 (34.0) |
| Frailty assessment | ||
| FRAIL-NH | ||
| Nonfrail | 20 (51.3) | 24 (51.1) |
| Pre-frail | 13 (13.3) | 18 (38.3) |
| Frail | 6 (15.38) | 5 (10.6) |
| SARC-F >3 (%) | 30 (76.9) | 38 (80.1) |
| Grip strength (IQR) (kg) | 11 (7–17) | 14 (7.5–18.5) |
| Barthel index (IQR) | 10 (4–14) | 9 (4–14) |
| Anti-Spike RBD antibody titer, U/mL (SD) | ||
| Baseline (pre-vaccination) | 160 (80–766) | 4 (0) |
| 5 wk after 2nd dose | 22,451 (14,021–25,000) | 633 (170–1848) |
| 6 mo after 2nd dose | 6332 (3372–9667) | 133 (54–337) |
NSAID, nonsteroidal anti-inflammatory drug.
Data are presented as means with SDs or medians with IQRs.